U.S. Markets open in 6 hrs 26 mins

Earnings Review and Free Research Report: Concord Medical Posted First Half-Yearly Results for FY17

LONDON, UK / ACCESSWIRE / September 18, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Concord Medical Services Holdings Ltd (NYSE: CCM) ("Concord Medical"), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=CCM, following the Company's disclosure of its financial results on August 25, 2017, for the first half of the fiscal year 2017 (H1 FY17). The Beijing, China-based Company's total net revenues fell a reported 19.0% y-o-y in H1 FY17. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:


At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CCM. With the links below you can directly download the report of your stock of interest free of charge at:


Earnings Reviewed

During the period ended June 30, 2017, Concord Medical reported revenues of RMB206.24 million ($30.42 million) compared to RMB254.64 million in the year-ago same period. The specialty hospital management Company's GAAP net loss attributable to ordinary shareholders came in at RMB101.78 million ($15.01 million) for H1 FY17 compared to RMB50.36 million in the year-ago corresponding period. The Company reported a diluted loss of RMB2.34 per American Depository Share (ADS) ($0.34 loss per ADS) in H1 FY17 versus a diluted loss of RMB1.15 per ADS in H1 FY16. Furthermore, non-GAAP net loss stood at RMB100.15 million, or RMB2.24 loss per ADS, for H1 FY17 compared to a non-GAAP net loss of RMB50.00 million, or RMB1.12 per ADS, in H1 FY16.

Operating Metrics

In H1 FY17, the Company incurred RMB134.97 million ($19.91 million) as a total cost of revenues, up from RMB153.08 million in H1 FY16. The Company posted a gross profit of RMB71.27 million ($10.51 million) in H1 FY17 versus RMB101.56 million in the prior year's comparable period. The Company's gross margin was 34.6% for H1 FY17 compared to 39.9% for the same period of last year.

Concord Medical's selling expenses were RMB30.51 million ($4.50 million) in H1 FY17 versus RMB41.41 million in H1 FY16. During H1 FY17, the Company's general and administrative expenses increased to RMB115.80 million ($17.08 million) from RMB75.47 million in the year-ago same period. The Company posted operating loss of RMB75.07 million ($11.07 million) in H1 FY17 compared to an operating loss of RMB15.33 million in H1 FY16. Furthermore, the Company posted negative adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) of RMB3.93 million in H1 FY17 versus a positive EBITDA of RMB68.59 million in H1 FY16.


In H1 FY17, Concord Medical's Network segment's revenues were RMB196.35 million ($28.96 million), falling 20.4% from RMB246.65 million in H1 FY16. The Company primarily attributed the decline in revenues to a closure of 18 centers in H1 FY17. Meanwhile, the Company operated a network of 60 centers in 34 cities in China as of June 30, 2017. The segment's gross profit was RMB86.8 million ($12.8 million) during H1 FY17 compared to RMB108.8 million in the first half of FY16. Meanwhile, gross profit margin was 44.2% for H1 FY17, up from 44.1% for the same period of last year.

Net revenues from the Hospital segment were RMB9.89 million ($1.46 million) during H1 FY17, rising 23.8% from RMB7.98 million in H1 FY16. Moreover, the segment reported a gross loss of RMB15.6 million ($2.3 million) in H1 FY17 compared to a gross loss of RMB7.2 million in H1 FY16.

Balance Sheet & Cash Flow

The Company ended the period with a cash and cash equivalents balance of RMB608.20 million ($89.71 million) compared to RMB189.91 million as of December 31, 2016. Additionally, the Company's long-term bank borrowings were down to RMB15.09 million ($2.23 million) as on June 30, 2017, from RMB215.671 million as of December 31, 2016.

Stock Performance

At the closing bell, on Friday, September 15, 2017, Concord Medical Services' stock was marginally down 0.25%, ending the trading session at $3.99. A total volume of 16.02 thousand shares have exchanged hands. The Company's stock price rallied 13.03% in the last three months. The stock currently has a market cap of $173.09 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily